Literature DB >> 27505108

Semiquantitative Volumetry by Sequential PET/CT May Improve Prediction of Complete Response to Neoadjuvant Chemoradiation in Patients With Distal Rectal Cancer.

Dalton A Dos Anjos1, Rodrigo O Perez, Angelita Habr-Gama, Guilherme P São Julião, Bruna B Vailati, Laura M Fernandez, João B de Sousa, Carlos A Buchpiguel.   

Abstract

BACKGROUND: Previous studies using PET/CT imaging have failed to accurately identify complete responders to neoadjuvant chemoradiation among patients with rectal cancer. The use of metabolic parameters alone or imprecise delineation of baseline and residual tumor volumes may have contributed for these disappointing findings.
OBJECTIVE: The purpose of this study was to determine the accuracy of complete response identification in rectal cancer after neoadjuvant chemoradiation by sequential PET/CT imaging with a decrease in tumor metabolism and volume using optimal tumor volume delineation.
DESIGN: This was a retrospective comparison of prospectively collected data from a clinical trial (National Clinical Trial 00254683). SETTINGS: The study was conducted at a single research center. PATIENTS: Ninety patients with cT2-4N0-2M0 distal rectal cancer underwent sequential PET/CT at baseline and 12 weeks after neoadjuvant chemoradiation. Quantitative metabolic analysis (median and maximal standard uptake values), volumetric estimates (metabolic tumor volume), and composite estimates incorporating volume and quantitative data (total lesion glycolysis) were compared for the assessment of response to neoadjuvant chemoradiation using receiver operating characteristic curves. Individual standard uptake value thresholds were used according to response to neoadjuvant chemoradiation to match metabolic activity and optimize volume delineation. MAIN OUTCOME MEASURES: The accuracy of complete response identification by multiple volumetric and metabolic parameters using sequential PET/CT imaging was measured.
RESULTS: Variation in total lesion glycolysis between baseline and 12-week PET/CT scans was associated with the best area under the curve (area under the curve = 0.81 (95% CI, 0.69-0.92)) when compared with standard uptake value or metabolic tumor volume for the identification of a complete responder. Patients with a ≥92% decrease in total lesion glycolysis between baseline and 12-week PET/CT scan had a 90% chance to harbor complete response. LIMITATIONS: This study was limited by its lack of interobserver agreement analysis.
CONCLUSIONS: PET/CT scan using volume and metabolic estimates with individual standard uptake value thresholds for volume determination may provide a useful tool to predict response to neoadjuvant chemoradiation in distal rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27505108     DOI: 10.1097/DCR.0000000000000655

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

Review 1.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  SSAT State-of-the-Art Conference: Advances in the Management of Rectal Cancer.

Authors:  Evie Carchman; Daniel I Chu; Gregory D Kennedy; Melanie Morris; Marc Dakermandji; John R T Monson; Laura Melina Fernandez; Rodrigo Oliva Perez; Alessandro Fichera; Marco E Allaix; David Liska
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

3.  Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.

Authors:  Niels W Schurink; Lisa A Min; Maaike Berbee; Wouter van Elmpt; Joost J M van Griethuysen; Frans C H Bakers; Sander Roberti; Simon R van Kranen; Max J Lahaye; Monique Maas; Geerard L Beets; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2020-02-07       Impact factor: 5.315

4.  FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer.

Authors:  Pierre Lovinfosse; Marc Polus; Daniel Van Daele; Philippe Martinive; Frédéric Daenen; Mathieu Hatt; Dimitris Visvikis; Benjamin Koopmansch; Frédéric Lambert; Carla Coimbra; Laurence Seidel; Adelin Albert; Philippe Delvenne; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-18       Impact factor: 9.236

Review 5.  'Watch and wait' in rectal cancer: summary of the current evidence.

Authors:  Jason On; Emad H Aly
Journal:  Int J Colorectal Dis       Date:  2018-07-05       Impact factor: 2.571

6.  Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease.

Authors:  Marcelo A Queiroz; Cinthia D Ortega; Felipe R Ferreira; Fernanda C Capareli; Sergio C Nahas; Giovanni G Cerri; Carlos A Buchpiguel
Journal:  Mol Imaging Biol       Date:  2021-11-09       Impact factor: 3.488

7.  Predictive Value of [18F]FDG PET/CT for Lymph Node Metastasis in Rectal Cancer.

Authors:  Sung Hoon Kim; Bong-Il Song; Beong Woo Kim; Hae Won Kim; Kyoung Sook Won; Sung Uk Bae; Woon Kyung Jeong; Seong Kyu Baek
Journal:  Sci Rep       Date:  2019-03-21       Impact factor: 4.379

8.  Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?

Authors:  Letizia Deantonio; Angela Caroli; Erinda Puta; Daniela Ferrante; Francesco Apicella; Lucia Turri; Gianmauro Sacchetti; Marco Brambilla; Marco Krengli
Journal:  Radiat Oncol       Date:  2018-10-25       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.